Supply Chain Leaders to Share Perspective on Tackling Tariffs, Trade, and Disruption During Exclusive Digital Event
OTTAWA, Ontario, June 12, 2025--(BUSINESS WIRE)--As global trade tensions remain at the forefront of business decision-making, Kinaxis® (TSX:KXS), a global leader in end-to-end supply chain orchestration, will host technology and life sciences supply chain leaders for a special tariff-focused digital event with economic futurist Andrew Busch on June 17, 2025 at 11:00am eastern.
Titled, Tariffs, Trade, and Turbulence: How to Respond to Today's Supply Chain Challenges, the event is tailored for global business leaders and will offer expert insights on how to navigate today's volatile trade environment with modern supply chain solutions to build resilient, future-ready supply chains.
"We're witnessing a seismic reshaping of global trade dynamics with leaders needing to decode the economic and geopolitical forces behind tariff policy while being able to anticipate what's coming next," said Andrew Busch, economic futurist and economist at AndrewBusch.com. "Tariffs are no longer just a policy lever; they're a strategic force reshaping the global economy with rules being rewritten in real time and disruption being the only constant."
Kinaxis is at the forefront of helping companies of all industries and sizes respond to today's tariff disruptions. Its leading AI-powered orchestration platform Maestro™ seamlessly connects all supply chain functions to create visibility, collaboration, and smarter decision making in the face of any disruption. During the U.S. presidential election, there was a dramatic increase in the number of what-if scenarios that companies ran on Maestro as they modeled and actioned potential impacts to sourcing, production, and logistics.
"The practice of supply chain management has fundamentally evolved, and disruptions like tariffs demonstrate the need for a modern approach that emphasizes speed, agility, and precision," said Andrew Bell, chief product officer at Kinaxis. "The speakers joining me during this discussion have made transformative supply chain change and bring first-hand experience around how they are using this new approach to navigate today's complex challenges. I look forward to highlighting their stories and to helping other companies take steps to better prepare their supply chains for today's realities."
Expert guest speakers include:
Andrew Busch, economic futurist and economist, will speak about the geopolitical and economic outlook on tariff policy, including insights into U.S.-China relations, global decoupling, and the future of trade
Brent Wilson, senior vice president global supply chain, Qualcomm will share his experiences navigating tariff-driven disruption and building supply chain resilience
Mark Walker, vice president supply chain, Viant Medical will share his experience strengthening the complex supply chain of Viant Medical through effective planning
Ken Vandrak, senior director, distribution and logistics, Thermo Fisher Scientific will discuss his experience in navigating the evolving trade landscape and overcoming logistical challenges in global distribution
Andrew Bell, chief product officer, Kinaxis will share his perspective on the role of AI, automation, and scenario planning in supply chains to drive faster, smarter decision making
Webinar: Tariffs, Trade, and Turbulence: How to Respond to Today's Supply Chain ChallengesDate: Tuesday, June 17Time: 11:00 AM ETRegistration Link: HERE
About Kinaxis
Kinaxis is a global leader in modern supply chain orchestration, powering complex global supply chains and supporting the people who manage them, in service of humanity. Our powerful, AI-infused supply chain orchestration platform, Maestro™ combines proprietary technologies and techniques that provide full transparency and agility across the entire supply chain — from multi-year strategic planning to last-mile delivery. We are trusted by renowned global brands to provide the agility and predictability needed to navigate today's volatility and disruption. For more news and information, please visit kinaxis.com or follow us on LinkedIn.
Source: Kinaxis Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250612438708/en/
Contacts
Media Relations Matt Tatham | Kinaxismtatham@kinaxis.com +1 917.446.7227Investor Relations Rick Wadsworth | Kinaxisrwadsworth@kinaxis.com +1 613-907-7613
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
7 hours ago
- Business Insider
TD Securities Reaffirms Their Buy Rating on Rogers Comm Cl A (RCI.A)
In a report released on July 24, Vince Valentini from TD Securities maintained a Buy rating on Rogers Comm Cl A, with a price target of C$58.00. The company's shares closed last Friday at C$50.15. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Valentini covers the Communication Services sector, focusing on stocks such as Rogers Communication, Rogers Comm Cl A, and Quebecor. According to TipRanks, Valentini has an average return of 0.8% and a 54.80% success rate on recommended stocks. In addition to TD Securities, Rogers Comm Cl A also received a Buy from Desjardins's Jerome Dubreuil in a report issued on July 24. However, on the same day, Scotiabank maintained a Hold rating on Rogers Comm Cl A (TSX: RCI.A). The company has a one-year high of C$59.00 and a one-year low of C$38.01. Currently, Rogers Comm Cl A has an average volume of 2,831.
Yahoo
16 hours ago
- Yahoo
Madrigal Pharmaceuticals, Inc. (MDGL)'s Rezdiffra Hits 51% Liver Stiffness Reduction in Phase 3
We recently compiled a list of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) is leading innovation in treating metabolic dysfunction-associated steatohepatitis (MASH), previously known as NASH. It's FDA-approved drug, Rezdiffra (resmetirom), is the first oral, liver-targeted thyroid hormone receptor-β agonist for MASH with moderate to advanced fibrosis (F2–F3). It is also being tested in compensated MASH cirrhosis patients. At the 2025 EASL Congress, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) presented promising two-year data from its Phase 3 MAESTRO-NAFLD-1 trial, showing Rezdiffra significantly reduced liver stiffness and lowered the risk of liver decompensation in F4c patients. Notably, 51% of participants had a ≥25% reduction in liver stiffness, and 65% of those with baseline portal hypertension moved to lower-risk categories. Safety remained consistent with prior results. Looking ahead, the MAESTRO-NASH OUTCOMES trial, expected to read out in 2027, will evaluate Rezdiffra's ability to reduce liver-related events in compensated cirrhosis patients. Meanwhile, regulatory momentum continues: the EMA's CHMP issued a positive opinion in June 2025, with potential EU approval expected by August. Rezdiffra would then be the first MASH treatment approved in both the U.S. and Europe. A healthcare professional wearing a health communications device discussing patient data with a colleague. Further solidifying its position, Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) secured a new U.S. patent for Rezdiffra's dosing rights in July 2025, enhancing its intellectual property and global commercialization strategy. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
a day ago
- Yahoo
China, Chips, and Chaos: Where Smart Investors Are Putting Their Money Now
As geopolitical tensions rise and global supply chains shift, investors around the world are focusing on one of today's most important industries: semiconductors. China is working hard to become self-sufficient in chip technology, whereas the U.S. is attempting to prevent the export of advanced chips in order to maintain its technological advantage. All this is happening while artificial intelligence (AI) advances at a rapid pace. These factors are creating a fast-moving, risky, but potentially lucrative market for investors. Amid the chaos, savvy investors prefer long-term stability to distraction. Here are two stocks that show where true innovation and resilience lie: More News from Barchart Dear Palantir Stock Fans, Mark Your Calendars for August 4 The 3 Buffett-Backed Dividend Stocks That Beat the Market in 2025 Should You Buy the Post-Earnings Plunge in Intel Stock? Tired of missing midday reversals? The FREE Barchart Brief newsletter keeps you in the know. Sign up now! Rising Star #1: Qualcomm Valued at $174.4 billion, Qualcomm (QCOM) develops and sells advanced semiconductors and wireless technologies, primarily for mobile phones, automotive systems, Internet of Things devices, and AI applications. It is best known for its Snapdragon processors. QCOM stock is up 3% year-to-date. Qualcomm's robust second quarter showcased the strength of its business model. Qualcomm reported a 15% increase in adjusted revenues to $10.8 billion year over year, with adjusted earnings of $2.85, representing 17% growth. The majority of this strength stemmed from the company's chip business, the Qualcomm CDMA Technologies (QCT) segment, which generated $9.5 billion. This was driven by strong growth in automotive (up 59%), IoT (up 27%), and handsets (up 12%). The Qualcomm Technology Licensing (QTL) licensing business contributed another $1.3 billion to overall revenue. Qualcomm continues to dominate the premium mobile market with its Snapdragon 8 Elite platform, which is regarded as one of the world's most powerful smartphone chipsets. Its Snapdragon X platform is also rapidly expanding into the PC market, to surpass its goal of 100 designs by 2026. Beyond mobile, Qualcomm is aggressively expanding into automotive, with the Snapdragon Digital Chassis platform helping it reach $8 billion in automotive revenue by fiscal 2029. Extended Reality (XR) is emerging as another growth driver, aided by Snapdragon technology and collaborations with Meta Platforms (META) and Samsung. The company intends to generate $2 billion in XR revenues by fiscal 2029. Qualcomm returned $2.7 billion to shareholders via dividends and buybacks, showing strong free cash flow generation and management confidence. The company has also committed to returning 100% of free cash flow to shareholders this fiscal year, citing strong fundamentals and a scalable model. Concerning China, Qualcomm continues to be a key player in the Chinese smartphone ecosystem, where local subsidies have increased flagship shipments. Management stated that the company's Q3 guidance takes current tariffs into account, also admitting that the trade landscape remains dynamic. Qualcomm has also taken steps to diversify its business, both geographically and across sectors, to reduce its reliance on a single region or product category. Overall, Wall Street rates QCOM stock a 'Moderate Buy.' Out of the 32 analysts that cover the stock, 15 rate it a 'Strong Buy,' one suggests a 'Moderate Buy,' 15 rate it a 'Hold,' and one rates it a 'Strong Sell.' Its average target price of $179.04 suggests an upside potential of 13% from current levels. Its high target price of $225 implies a potential upside of 42% in the next 12 months. Rising Star #2: Broadcom Valued at $1.3 trillion, Broadcom (AVGO) designs, develops, and distributes a wide range of semiconductor and infrastructure software products. Its diverse portfolio includes networking chips, enterprise storage, broadband, and wireless communication. Broadcom also provides enterprise software solutions for cybersecurity, storage, and mainframes. AVGO stock is up 24.8% year to date, outperforming the broader market. Broadcom reported staggering revenue of $15 billion in the second quarter, up 20% year over year. AI semiconductor revenue soared to $4.4 billion, up 46%, marking nine consecutive quarters of consistent growth. This growth was driven by custom AI accelerators (chips designed for specific hyperscaler clients) and AI networking, which account for 40% of AI semiconductor revenue. Management confidently forecasts 60% AI revenue growth in Q3 2025, which is expected to continue into fiscal 2026, cementing AI semiconductors as its long-term growth driver. Furthermore, software is no longer a side hustle for Broadcom. It has strengthened its position in software through strategic acquisitions such as VMware for $69 billion, which officially closed in 2024. Its infrastructure software segment generated $6.6 billion in revenue, up 25% YoY, accounting for 44% of total company revenue. Over 87% of Broadcom's top 10,000 customers now use VMware Cloud Foundation (VCF). Furthermore, the company is converting customers from perpetual licenses to subscription-based ARR, resulting in more predictable revenue. Looking ahead, major cloud players are expected to continue to invest, demand for training and inference workloads will rise, and software adoption will remain strong, painting a positive long-term outlook. Broadcom is not only growing rapidly, but also profitably. Adjusted earnings increased 44% to $1.58 per share in Q2. The company also generated $6.4 billion in free cash flow, paying out $2.8 billion in dividends and $4.2 billion worth of share repurchases. Despite rising U.S.-China tech tensions, Broadcom is well-positioned to thrive. It does not rely heavily on high-end GPUs with export restrictions. Overall, Wall Street rates AVGO stock a 'Strong Buy.' Out of the 36 analysts that cover the stock, 32 rate it a 'Strong Buy,' one suggests a 'Moderate Buy,' and three rate it a 'Hold.' Its average target price of $298.55 suggests an upside potential of 3% from current levels. Its high target price of $400 implies a potential upside of 38% in the next 12 months. The Key Takeaway No doubt, the U.S.-China chip war presents significant challenges. Export controls, shifting alliances, and technology bans may all cause short-term turbulence. However, the best way to profit from the semiconductor boom may be to invest in companies that can adapt, endure, and grow in uncertain times. Both Qualcomm and Broadcom serve this purpose. On the date of publication, Sushree Mohanty did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
